{"id":"tp-42262","type":"article-newspaper","title":"AbbVie Seeks FDA Review of Etentamig for Relapsed or Refractory Myeloma","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/42262","datePublished":"2026-10-28T02:25:29.000Z","dateModified":"2026-10-28T02:25:29.000Z","language":"en","abstract":"In Phase 3 CERVINO, the response rate was 74.0% with etentamig and 45.7% with standard therapy after a median 11.4 months of follow-up.","section":"Regulation","references":[{"title":"a Phase 3 trial after at least one prior treatment line","url":"https://www.tokenpost.com/news/business/41943"}]}